Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Anhui Kedgene Biotechnology

Main focus: Next generation T cell-based therapies

Company stage: Clinical

Diseases: Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Anhui, China

Website: https://www.ankebio.com/english/index.php

Anhui Kedgene Biotechnology develops next generation T cell-based therapies for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimise efficacy and safety.

Tags

HashtagAnhui Kedgene Biotechnology Co.,Ltd

Company: Anhui Kedgene Biotechnology
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine